Repositioning Candidate Details

Candidate ID: R0503
Source ID: DB01369
Source Type: approved
Compound Type: small molecule
Compound Name: Quinupristin
Synonyms: Quinupristin
Molecular Formula: C53H67N9O10S
SMILES: [H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
Structure:
DrugBank Description: Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. The combination of the two components acts synergistically and is more effective in vitro than each component alone.
CAS Number: 120138-50-3
Molecular Weight: 1022.23
DrugBank Indication: For the treatment of bacterial infections (usually in combination with dalfopristin).
DrugBank Pharmacology: Quinupristin is a streptogramin antibiotic, derived from pristinamycin I. By inhibiting the bacterial ribosomal subunits, protein synthesis is inhibited thus leading to eventual bacterial cell death or stasis.
DrugBank MoA: Quinupristin inhibits the late phase of protein synthesis in the bacterial ribosome. Dalfopristin binds to the 23S portion of the 50S ribosomal subunit, and changes the conformation it, enhancing the binding of quinupristin by a factor of about 100. In addition, it inhibits peptidyl transferase. Quinupristin binds to a nearby site on the 50S ribosomal subunit and prevents elongation of the polypeptide as well as causing incomplete chains to be released.
Targets: 23S ribosomal RNA inhibitor; 50S ribosomal protein L10 inhibitor; 50S ribosomal protein L22 inhibitor
Inclusion Criteria: Indication associated